Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Squamous Cell × 30 days × Clear all

Phase

Phase 2 8 Phase NA 3 Phase 1/2 3 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 70 Breast Neoplasms 45 Prostatic Neoplasms 29 Neoplasms 26 Multiple Myeloma 25 Parkinson Disease 4, Autosomal Dominant Lewy Body 20 Lung Neoplasms 19 Leukemia, Lymphocytic, Chronic, B-Cell 18 Ovarian Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 16 Myasthenia Gravis 16 Leukemia, Myeloid, Acute 15 Colorectal Neoplasms 15 Neoplasm Metastasis 14 Melanoma 14 Lymphoma, Follicular 14 Urinary Bladder Neoplasms 12 Stomach Neoplasms 12 Carcinoma, Renal Cell 12 Recurrence 10 Carcinoma 10 Small Cell Lung Carcinoma 9 Non-Muscle Invasive Bladder Neoplasms 9 Lymphoma, Non-Hodgkin 8 Fallopian Tube Neoplasms 8 Endometrial Neoplasms 8 Uterine Cervical Neoplasms 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma 7 Head and Neck Neoplasms 7

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03833167 2026-03-10

KEYNOTE-630

Merck Sharp & Dohme LLC

Phase 3 Completed

450 enrolled 18 charts

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡